Artwork

Innhold levert av DKBmed. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av DKBmed eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Emerging MS Clinical Options

24:18
 
Del
 

Manage episode 385239857 series 2065653
Innhold levert av DKBmed. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av DKBmed eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

214 episoder

Artwork

Emerging MS Clinical Options

DKBmed Radio

19 subscribers

published

iconDel
 
Manage episode 385239857 series 2065653
Innhold levert av DKBmed. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av DKBmed eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

214 episoder

All episodes

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett